Abstract:Background: Lung adenocarcinoma (LUAD) is a heterogeneous tumor characterized by diverse genetic and molecular alterations. Developing a multi-omics-based classification system for LUAD is urgently needed to advance biological understanding. Methods: Data on clinical and pathological characteristics, genetic alterations, DNA methylation patterns, and the expression of mRNA, lncRNA, and microRNA, along with somatic mutations in LUAD patients, were gathered from the TCGA and GEO datasets. A computational workflow was utilized to merge multi-omics data from LUAD patients through 10 clustering techniques, which were paired with 10 machine learning methods to pinpoint detailed molecular subgroups and refine a prognostic risk model. The disparities in somatic mutations, copy number alterations, and immune cell infiltration between high- and low-risk groups were assessed. The effectiveness of immunotherapy in patients was evaluated through the TIDE and SubMap algorithms, supplemented by data from various immunotherapy groups. Furthermore, the Cancer Therapeutics Response Portal (CTRP) and the PRISM Repurposing dataset (PRISM) were employed to investigate new drug treatment approaches for LUAD. In the end, the role of SLC2A1 in tumor dynamics was examined using RT-PCR, immunohistochemistry, CCK-8, wound healing, and transwell tests. Results: By employing multi-omics clustering, we discovered two unique cancer subtypes (CSs) linked to prognosis, with CS2 demonstrating a better outcome. A strong model made up of 17 genes was created using a random survival forest (RSF) method, which turned out to be an independent predictor of overall survival and showed reliable and impressive performance. The low-risk group not only had a better prognosis but also was more likely to display the "cold tumor" phenotype. On the other hand, individuals in the high-risk group showed a worse outlook and were more likely to respond positively to immunotherapy and six particular chemotherapy medications. Laboratory cell tests demonstrated that SLC2A1 is abundantly present in LUAD tissues and cells, greatly enhancing the proliferation and movement of LUAD cells. Conclusions: Thorough examination of multi-omics data offers vital understanding and improves the molecular categorization of LUAD. Utilizing a powerful machine learning system, we highlight the immense potential of the riskscore in providing individualized risk evaluations and customized treatment suggestions for LUAD patients.

Classifying Lung Adenocarcinoma and Squamous Cell Carcinoma Using RNA-Seq Data

Evaluation of A Lung Cancer Rna Expression Subtyping Panel and Comparison with Histologic Diagnosis in Lung Tumor Samples from Multiple Data Sets Including the Cancer Genome Atlas (Tcga).

Identification of expression signatures for non-small-cell lung carcinoma subtype classification

An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer

Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma

Machine-learning and scRNA-Seq-based diagnostic and prognostic models illustrating survival and therapy response of lung adenocarcinoma

Classification of Human Lung Carcinomas by Mrna Expression Profiling Reveals Distinct Adenocarcinoma Subclasses

Subclassification of lung adenocarcinoma through comprehensive multi-omics data to benefit survival outcomes

A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis

Genome‐wide Copy Number Variation Pattern Analysis and a Classification Signature for Non‐small Cell Lung Cancer

Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods

A novel nomogram model for lung adenocarcinoma subtypes based on RNA-modification regulatory genes

Analysis of Gene Expression Profiles of Lung Cancer Subtypes with Machine Learning Algorithms.

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma

Identifying Lung Cancer Cell Markers with Machine Learning Methods and Single-Cell RNA-Seq Data

Analysis of Lncrna Expression Profiles in Non-Small Cell Lung Cancers (NSCLC) and Their Clinical Subtypes

Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion

Classification of Non-Small Cell Lung Cancer Using Significance Analysis of Microarray-Gene Set Reduction Algorithm

Multi-omics characterization and machine learning of lung adenocarcinoma molecular subtypes to guide precise chemotherapy and immunotherapy

Single-cell Data Analysis of Malignant Epithelial Cell Heterogeneity in Lung Adenocarcinoma for Patient Classification and Prognosis Prediction.

Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma